Assembly Biosciences (ASMB) EBITDA Margin (2017 - 2026)
Assembly Biosciences (ASMB) posted quarterly EBITDA Margin of 138.44% for Q1 2026, down 3290.0% year-over-year from 4.34% in Q1 2025, and down 396.95% quarter-over-quarter from 46.62% in Q4 2025.
Assembly Biosciences (ASMB) EBITDA Margin (2017 - 2026) Analysis & Trends
Assembly Biosciences' EBITDA Margin history runs 9 years deep, the most recent figure standing at 138.44% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 3290.0% year-over-year to 138.44%; the TTM figure through Mar 2026 stood at 19.05% (up 11975.0% YoY), while the FY2025 annual figure was 16.76%, up 14250.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 138.44%, down from 46.62% in the prior quarter.
- The five-year high for EBITDA Margin was 46.62% in Q4 2025, with the low at 185.46% in Q1 2024.
- The 4-year median for EBITDA Margin is 140.72% (2026), against an average of 123.4%.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 20337 bps in 2025, then sank 3290 bps in 2026.
- Assembly Biosciences' EBITDA Margin stood at 175.22% in 2023, then increased by 11 bps to 156.75% in 2024, then soared by 130 bps to 46.62% in 2025, then tumbled by 397 bps to 138.44% in 2026.
- Business Quant data shows ASMB's EBITDA Margin at 138.44% in Q1 2026, 46.62% in Q4 2025, and 100.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | -47.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.44% |
| Mar 31, 2026 | -138.44% |
| Dec 31, 2025 | 46.62% |
| Sep 30, 2025 | -100.87% |
| Jun 30, 2025 | -115.24% |
| Mar 31, 2025 | -105.54% |
| Dec 31, 2024 | -156.75% |
| Sep 30, 2024 | -160.06% |
| Jun 30, 2024 | -143.01% |
| Mar 31, 2024 | -185.46% |
| Dec 31, 2023 | -175.22% |
| Sep 30, 2021 | -301.81% |
| Dec 31, 2020 | -3,822.76% |
| Sep 30, 2020 | -11.61% |
| Jun 30, 2020 | 16.71% |
| Mar 31, 2020 | -678.61% |
| Dec 31, 2019 | -601.72% |
| Sep 30, 2019 | -614.35% |
| Jun 30, 2019 | -639.61% |
| Mar 31, 2019 | -729.37% |